ArticleMedComm2026
Dynamic Immune Reconstitution and Clinical Outcomes of Three Different Protocols for Haploidentical Hematopoietic Stem Cell Transplantation.
Xiao-Di Ma, Jie Ji, Zheng-Li Xu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Yu-Qian Sun, Xiao-Dong Mo, Yi-Fei Cheng, Hui-Dong Guo and 2 more
Abstract read
In one paragraphArticle in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Xiao-Di MaPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Jie JiStem Cell Transplantation & Cellular Therapy Division Clinic Trial Center Institute of Hematology Department of Hematology West China Hospital Sichuan University Chengdu China.
Zheng-Li XuPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Lan-Ping XuPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Yu WangPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Xiao-Hui ZhangPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Yu-Qian SunPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Xiao-Dong MoPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Yi-Fei ChengPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Hui-Dong GuoPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.
Tian DongStem Cell Transplantation & Cellular Therapy Division Clinic Trial Center Institute of Hematology Department of Hematology West China Hospital Sichuan University Chengdu China.
Xiao-Jun HuangPeking University Institute of Hematology Peking University People's Hospital Peking University Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation National Clinical Research Center for Hematologic Disease Beijing China.ORCID https://orcid.org/0000-0002-2145-6643 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The wider application of posttransplant cyclophosphamide (PTCY) and granulocyte colony-stimulating factor (G-CSF)/antithymocyte globulin (ATG)-based protocols has revolutionized haploidentical hematopoietic stem cell transplantation (haplo-HSCT) by decreasing graft-versus-host disease and facilitating engraftment. In this study, we compared the clinical outcomes and the immune reconstitution of propensity score-matched (1:1:1) patients receiving PTCY (
Indexed as
Beijing protocolconditioning regimenhaploidentical hematopoietic stem cell transplantationimmune reconstitutionposttransplant cyclophosphamide
Identifiers
PMID42253920
PMCPMC13239405
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390